Jackeline de Souza Rangel Machado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4963799/publications.pdf

Version: 2024-02-01

1170033 1051228 16 291 9 16 citations h-index g-index papers 17 17 17 400 docs citations citing authors all docs times ranked

#	Article	IF	Citations
1	Resveratrol and grape juice: Effects on redox status and nitric oxide production of endothelial cells in in vitro preeclampsia model. Pregnancy Hypertension, 2021, 23, 205-210.	0.6	14
2	Multiprofessional care promotes of quality of life in pregnant women with preeclampsia: a cross-sectional study. Clinics, 2020, 75, e1951.	0.6	2
3	C>T (rs17035945) polymorphism of TIMP-4 protects against preeclampsia. Journal of Obstetrics and Gynaecology, 2019, 39, 135-137.	0.4	3
4	Safety of a physical therapy protocol for women with preeclampsia: a randomized controlled feasibility trial. Hypertension in Pregnancy, 2018, 37, 59-67.	0.5	3
5	Role of adiponectin on antioxidant profile: evaluation during healthy and hypertensive disorders of pregnancy. Blood Pressure, 2016, 25, 241-243.	0.7	9
6	Longitudinal assessment of maternal-fetal Doppler parameters and maternal plasma level of matrix metalloproteinases 2 and 9. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 3967-3970.	0.7	2
7	Assessment of nitrite oxide and maternal–fetal Doppler parameters during pregnancy. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1-4.	0.7	0
8	Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant. Pregnancy Hypertension, 2015, 5, 205-208.	0.6	39
9	Polymorphisms of the adiponectin gene in gestational hypertension and pre-eclampsia. Journal of Human Hypertension, 2014, 28, 128-132.	1.0	16
10	Correlations between circulating levels of adipokines and anti-angiogenic factors in women with BMI <30 and a late-onset preeclampsia. Hypertension in Pregnancy, 2014, 33, 72-80.	0.5	13
11	Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics Journal, 2014, 14, 535-541.	0.9	38
12	Assessment of oxidative status markers and NO bioavailability in hypertensive disorders of pregnancy. Journal of Human Hypertension, 2013, 27, 345-348.	1.0	16
13	Maternal Flow-Mediated Dilation and Nitrite Concentration During Third Trimester of Pregnancy and Postpartum Period. Hypertension in Pregnancy, 2013, 32, 225-234.	0.5	7
14	Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics Journal, 2012, 12, 489-498.	0.9	46
15	Effects of Matrix Metalloproteinase (<scp>MMP</scp>)â€⊋ Polymorphisms on Responsiveness to Antihypertensive Therapy of Women with Hypertensive Disorders of Pregnancy. Basic and Clinical Pharmacology and Toxicology, 2012, 111, 262-267.	1.2	21
16	Association between matrix metalloproteinase (MMP)-2 polymorphisms and MMP-2 levels in hypertensive disorders of pregnancy. Experimental and Molecular Pathology, 2012, 92, 217-221.	0.9	57